ARTICLE | Clinical News

Phase I remissions boost Agios

November 20, 2014 2:37 AM UTC

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) rose $12.16 (15%) to $95.97 after it said four of 14 evaluable patients had complete remissions in a Phase I trial of AG-120 to treat advanced hematologic malignancies including acute myelogenous leukemia (AML). The trial enrolled patients with an isocitrate dehydrogenase I (IDH1) mutation who had failed at least one prior therapy, and included four dose levels.

Seven patients achieved objective responses, including two marrow complete remissions and one partial remission. Agios said early evidence showed durability of remission from 15 days to five months among the four complete remissions. It added that the maximum tolerated dose has not been achieved. ...